Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Overview of attention for article published in Hepatology, February 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#47 of 11,413)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 40 news outlets
twitter: 12 X users
patent: 12 patents

wikipedia: 3 Wikipedia pages
guideline: 1 clinical guideline source

Readers on

mendeley: 142 Mendeley

So far, Altmetric has seen 13 X posts from 12 X users, with an upper bound of 57,377 followers.

Words I just don’t get, I look up & read more until I do. As here: https://t.co/ysOpjCWRy5 https://t.co/7ta23TpOU4 ;just lists affiliatns of 1 of the authors, topic not #COVID19. I’d searched his company Liponexus Inc.

出典以下: 記事① https://t.co/rR98HHHed3 記事② https://t.co/K6qRxAKfe2

RT @DrLoomba: Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis due to NASH https://t.co/IjRiWf…

RT @DrLoomba: Cilofexor and firsocostat in ATLAS https://t.co/h9rvakheaY Compared to placebo, higher proportions of CILO/FIR patients had a…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 9 additional X posts.